182 related articles for article (PubMed ID: 32410591)
1. Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials.
Nie RC; Zou XB; Yuan SQ; Chen YB; Chen S; Chen YM; Chen GM; Chen XJ; Luo TQ; Li SM; Duan JL; Wang Y; Li YF
BMC Cancer; 2020 May; 20(1):421. PubMed ID: 32410591
[TBL] [Abstract][Full Text] [Related]
2. Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials.
Petrelli F; Tomasello G; Ghidini M; Lonati V; Passalacqua R; Barni S
HPB (Oxford); 2017 Nov; 19(11):944-950. PubMed ID: 28764887
[TBL] [Abstract][Full Text] [Related]
3. Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.
Ajani JA; Leung L; Singh P; Kurt M; Kim I; Pourrahmat MM; Kanters S
Eur J Cancer; 2022 Jul; 170():119-130. PubMed ID: 35605522
[TBL] [Abstract][Full Text] [Related]
4. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis.
Oba K; Paoletti X; Alberts S; Bang YJ; Benedetti J; Bleiberg H; Catalano P; Lordick F; Michiels S; Morita S; Ohashi Y; Pignon JP; Rougier P; Sasako M; Sakamoto J; Sargent D; Shitara K; Cutsem EV; Buyse M; Burzykowski T;
J Natl Cancer Inst; 2013 Nov; 105(21):1600-7. PubMed ID: 24108812
[TBL] [Abstract][Full Text] [Related]
5. Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials.
Makris EA; MacBarb R; Harvey DJ; Poultsides GA
Ann Surg Oncol; 2017 Aug; 24(8):2371-2378. PubMed ID: 28397190
[TBL] [Abstract][Full Text] [Related]
6. Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis.
Untch M; Pérol D; Mayer EL; Cortes J; Nusch A; Cameron D; Barrios C; Delea T; Danyliv A; Mishra N; Gupta R; Pathak P; Fasching PA
Eur J Cancer; 2024 May; 202():113977. PubMed ID: 38460476
[TBL] [Abstract][Full Text] [Related]
7. Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.
Nie RC; Yuan SQ; Wang Y; Zou XB; Chen S; Li SM; Duan JL; Zhou J; Chen GM; Luo TQ; Zhou ZW; Li YF
Ther Adv Med Oncol; 2020; 12():1758835920929583. PubMed ID: 32595775
[TBL] [Abstract][Full Text] [Related]
8. The importance of time-to-adjuvant treatment on survival with pancreatic cancer: A systematic review and meta-analysis.
Sugumar K; Hue JJ; De La Serna S; Rothermel LD; Ocuin LM; Hardacre JM; Ammori JB; Winter JM
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1390. PubMed ID: 34245139
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.
Harshman LC; Xie W; Moreira RB; Bossé D; Ruiz Ares GJ; Sweeney CJ; Choueiri TK
Cancer; 2018 Mar; 124(5):925-933. PubMed ID: 29266178
[TBL] [Abstract][Full Text] [Related]
10. Surrogacy of Recurrence-free Survival for Overall Survival as an Endpoint of Clinical Trials of Perioperative Adjuvant Therapy in Hepatobiliary-pancreatic Cancers: A Retrospective Study and Meta-analysis.
Imamura T; Ohgi K; Mori K; Ashida R; Yamada M; Otsuka S; Uesaka K; Sugiura T
Ann Surg; 2024 Jun; 279(6):1025-1035. PubMed ID: 37638472
[TBL] [Abstract][Full Text] [Related]
11. Individual- and trial-level surrogacy in colorectal cancer.
Buyse M; Burzykowski T; Michiels S; Carroll K
Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
[TBL] [Abstract][Full Text] [Related]
12. Disease-free survival as a measure of overall survival in resected pancreatic endocrine neoplasms.
Ricci C; Partelli S; Ingaldi C; Andreasi V; Campana D; Muffatti F; Alberici L; Giorgi C; Casadei R; Falconi M
Endocr Relat Cancer; 2020 Mar; 27(5):275-283. PubMed ID: 32053492
[TBL] [Abstract][Full Text] [Related]
13. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
[TBL] [Abstract][Full Text] [Related]
14. Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer.
Gogate A; Ranjan S; Kumar A; Bhandari H; Papademetriou E; Kim I; Potluri R
Front Oncol; 2023; 13():1119102. PubMed ID: 37205193
[TBL] [Abstract][Full Text] [Related]
15. Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials.
Yin J; Salem ME; Dixon JG; Jin Z; Cohen R; DeGramont A; Van Cutsem E; Taieb J; Alberts SR; Wolmark N; Schmoll HJ; Saltz LB; George TJ; Goldberg RRM; Kerr R; Lonardi S; Yoshino T; Yothers G; Grothey A; Andre T; Shi Q
J Natl Cancer Inst; 2022 Jan; 114(1):60-67. PubMed ID: 34505880
[TBL] [Abstract][Full Text] [Related]
16. Surrogate endpoints for overall survival in lung cancer trials: a review.
Fiteni F; Westeel V; Bonnetain F
Expert Rev Anticancer Ther; 2017 May; 17(5):447-454. PubMed ID: 28399678
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials.
Nie RC; Chen FP; Yuan SQ; Luo YS; Chen S; Chen YM; Chen XJ; Chen YB; Li YF; Zhou ZW
Eur J Cancer; 2019 Jan; 106():1-11. PubMed ID: 30453169
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness of adjuvant chemotherapy for Stage I pancreatic cancer based on the UICC 8
Hamura R; Haruki K; Fujiwara Y; Tsunematsu M; Shirai Y; Furukawa K; Onda S; Gocho T; Shiba H; Uwagawa T; Usuba T; Fujioka S; Okamoto T; Ikegami T
Langenbecks Arch Surg; 2022 Dec; 407(8):3437-3446. PubMed ID: 36173461
[TBL] [Abstract][Full Text] [Related]
19. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
[TBL] [Abstract][Full Text] [Related]
20. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
Abrams RA; Grochow LB; Chakravarthy A; Sohn TA; Zahurak ML; Haulk TL; Ord S; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL; Yeo CJ
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1039-46. PubMed ID: 10421536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
